Viking Therapeutics aims to price $10 million public stock offering

Deal funds clinical development, working capital, corporate purposes

By Devika Patel

Knoxville, Tenn., Nov. 24 – Viking Therapeutics, Inc. will conduct a $10 million public sale of its common stock with a 45-day greenshoe, according to a form S-1 filed Tuesday with the Securities and Exchange Commission. The company has registered up to $11.5 million of stock.

Proceeds will be used for clinical development, working capital and other general corporate purposes.

The biopharmaceutical company is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.